Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Active not recruiting 24Recruiting 22Not yet recruiting 4Completed 4Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4Hematologic Diseases 1

Interventions

pembrolizumab 21Cisplatin 14Carboplatin 13Paclitaxel 12Radiation 11Radiotherapy 10Doxorubicin 10Nivolumab 9Cyclophosphamide 9Cytarabine 8Vincristine 7Radiotherapy, Intensity-Modulated 7Metformin 7Magnetic Resonance Spectroscopy 7Injections 7Etoposide 7Leucovorin 6Ipilimumab 6Fluorouracil 6Docetaxel 6tislelizumab 5Specimen Handling 5Radiotherapy, Conformal 5Radiosurgery 5Prednisone 5Pemetrexed 5Methotrexate 5Dexamethasone 5Cetuximab 5Bevacizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Lenalidomide × 30 days × Clear all
NCT01702831 2026-06-05

BuMelMCRN001

University Health Network, Toronto

Phase 2 Completed
78 enrolled
Plasma cell

Multiple Myeloma

NCT03652064 2026-06-02

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Janssen Research & Development, LLC

Phase 3 Completed
395 enrolled 11 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT03106324 2026-05-28

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

Celgene

Completed
911 enrolled
Plasma cell

Multiple Myeloma

NCT05032820 2026-05-19

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Medical College of Wisconsin

Phase 2 Completed
40 enrolled 32 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡